56,799 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by LMR Partners LLP

LMR Partners LLP acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 56,799 shares of the biopharmaceutical company's stock, valued at approximately $5,247,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Czech National Bank increased its position in Gilead Sciences by 6.5% during the 4th quarter. Czech National Bank now owns 270,216 shares of the biopharmaceutical company's stock worth $24,960,000 after buying an additional 16,598 shares during the period. Aprio Wealth Management LLC increased its holdings in shares of Gilead Sciences by 124.7% during the fourth quarter. Aprio Wealth Management LLC now owns 7,766 shares of the biopharmaceutical company's stock worth $717,000 after purchasing an additional 4,310 shares during the period. Matrix Trust Co raised its position in shares of Gilead Sciences by 515.2% in the fourth quarter. Matrix Trust Co now owns 1,052 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 881 shares in the last quarter. Brookstone Capital Management increased its stake in Gilead Sciences by 0.4% during the 4th quarter. Brookstone Capital Management now owns 147,452 shares of the biopharmaceutical company's stock worth $13,620,000 after acquiring an additional 600 shares during the period. Finally, Capital Investment Advisors LLC lifted its position in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock valued at $35,793,000 after acquiring an additional 9,791 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 2.2%

Shares of NASDAQ:GILD traded up $2.16 during midday trading on Friday, reaching $102.50. The company's stock had a trading volume of 6,395,303 shares, compared to its average volume of 7,649,762. The firm has a 50 day moving average price of $105.99 and a two-hundred day moving average price of $99.58. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market capitalization of $127.63 billion, a price-to-earnings ratio of 277.03, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 3.08%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 25,429 shares of company stock worth $2,894,445 in the last ninety days. Corporate insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.